REQUEST A DEMO
Total
USD $0.00
Search more companies

Neveon Foam D.O.O. (Serbia)

Main Activities: Plastics Material and Resin Manufacturing
Full name: Neveon Foam D.O.O. Profile Updated: October 16, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Neveon Foam D.O.O is a pharmaceutical company specializing in neonatology, oncology, and hematology. The company represents and distributes medicines from foreign pharmaceutical companies in the market and holds licenses for drugs such as Bleocin, Curosurf poraktant alpha lungs surfactant, and Peyona caffeine citrate. Neveon Foam D.O.O. aims to advance the pharmaceutical markets and has contributed to significant improvements in neonatology and cytostatic therapy.

Headquarters
Karadjordjeva BB
Stara Pazova; Srem; Postal Code: www.eurofarm.rs

Contact Details: Purchase the Neveon Foam D.O.O. report to view the information.

Website: http://CUBE_PROFILES_YU

Basic Information
Total Employees:
Purchase the Neveon Foam D.O.O. report to view the information.
Outstanding Shares:
Purchase the Neveon Foam D.O.O. report to view the information.
Registered Capital:
Purchase the Neveon Foam D.O.O. report to view the information.
Incorporation Date:
July 18, 2003
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Representative
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Neveon Foam D.O.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
-16.84%
Total operating revenue
-16.68%
Operating profit (EBIT)
N/A
EBITDA
593.97%
Net Profit (Loss) for the Period
-81.38%
Total assets
-11%
Total equity
-3.2%
Operating Profit Margin (ROS)
N/A
Net Profit Margin
-0.9%
Return on Equity (ROE)
-1.54%
Debt to Equity Ratio
0.65%
Quick Ratio
4.59%
Cash Ratio
0.94%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?